tetano
Editor, Senior Moderator
Virology
. 2024 Jun 19:597:110149.
doi: 10.1016/j.virol.2024.110149. Online ahead of print. Peptide S4 is an entry inhibitor of SARS-CoV-2 infection
Zhiyu Liang[SUP] 1 [/SUP], Jiamei Wang[SUP] 2 [/SUP], Huan Zhang[SUP] 3 [/SUP], Lixia Gao[SUP] 2 [/SUP], Jun Xu[SUP] 4 [/SUP], Peiran Li[SUP] 2 [/SUP], Jie Yang[SUP] 2 [/SUP], Xinting Fu[SUP] 2 [/SUP], Han Duan[SUP] 2 [/SUP], Jiayan Liu[SUP] 5 [/SUP], Tiancai Liu[SUP] 6 [/SUP], Weifeng Ma[SUP] 7 [/SUP], Kun Wu[SUP] 8 [/SUP]
Affiliations
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a significant socioeconomic burden, and combating COVID-19 is imperative. Blocking the SARS-CoV-2 RBD-ACE2 interaction is a promising therapeutic approach for viral infections, as SARS-CoV-2 binds to the ACE2 receptors of host cells via the RBD of spike proteins to infiltrate these cells. We used computer-aided drug design technology and cellular experiments to screen for peptide S4 with high affinity and specificity for the human ACE2 receptor through structural analysis of SARS-CoV-2 and ACE2 interactions. Cellular experiments revealed that peptide S4 effectively inhibited SARS-CoV-2 and HCoV-NL63 viruses from infecting host cells and was safe for cells at effective concentrations. Based on these findings, peptide S4 may be a potential pharmaceutical agent for clinical application in the treatment of the ongoing SARS-CoV-2 pandemic.
Keywords: Angiotensin-converting enzyme 2; Entry inhibitor; S protein; SARS-CoV-2.
. 2024 Jun 19:597:110149.
doi: 10.1016/j.virol.2024.110149. Online ahead of print. Peptide S4 is an entry inhibitor of SARS-CoV-2 infection
Zhiyu Liang[SUP] 1 [/SUP], Jiamei Wang[SUP] 2 [/SUP], Huan Zhang[SUP] 3 [/SUP], Lixia Gao[SUP] 2 [/SUP], Jun Xu[SUP] 4 [/SUP], Peiran Li[SUP] 2 [/SUP], Jie Yang[SUP] 2 [/SUP], Xinting Fu[SUP] 2 [/SUP], Han Duan[SUP] 2 [/SUP], Jiayan Liu[SUP] 5 [/SUP], Tiancai Liu[SUP] 6 [/SUP], Weifeng Ma[SUP] 7 [/SUP], Kun Wu[SUP] 8 [/SUP]
Affiliations
- PMID: 38917689
- DOI: 10.1016/j.virol.2024.110149
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a significant socioeconomic burden, and combating COVID-19 is imperative. Blocking the SARS-CoV-2 RBD-ACE2 interaction is a promising therapeutic approach for viral infections, as SARS-CoV-2 binds to the ACE2 receptors of host cells via the RBD of spike proteins to infiltrate these cells. We used computer-aided drug design technology and cellular experiments to screen for peptide S4 with high affinity and specificity for the human ACE2 receptor through structural analysis of SARS-CoV-2 and ACE2 interactions. Cellular experiments revealed that peptide S4 effectively inhibited SARS-CoV-2 and HCoV-NL63 viruses from infecting host cells and was safe for cells at effective concentrations. Based on these findings, peptide S4 may be a potential pharmaceutical agent for clinical application in the treatment of the ongoing SARS-CoV-2 pandemic.
Keywords: Angiotensin-converting enzyme 2; Entry inhibitor; S protein; SARS-CoV-2.